HomeCompareFRSHY vs JNJ

FRSHY vs JNJ: Dividend Comparison 2026

FRSHY yields 2.05% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 JNJ wins by $10.2K in total portfolio value· pulled ahead in Year 5
10 years
FRSHY
FRSHY
● Live price
2.05%
Share price
$7.50
Annual div
$0.15
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.0K
Annual income
$0.20
Full FRSHY calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — FRSHY vs JNJ

📍 JNJ pulled ahead of the other in Year 5

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodFRSHYJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, FRSHY + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
FRSHY pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

FRSHY
Annual income on $10K today (after 15% tax)
$174.51/yr
After 10yr DRIP, annual income (after tax)
$0.17/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, JNJ beats the other by $3,985.82/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of FRSHY + JNJ for your $10,000?

FRSHY: 50%JNJ: 50%
100% JNJ50/50100% FRSHY
Portfolio after 10yr
$25.2K
Annual income
$2,344.80/yr
Blended yield
9.32%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

FRSHY
No analyst data
Altman Z
0.5
Piotroski
4/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

FRSHY buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricFRSHYJNJ
Forward yield2.05%2.13%
Annual dividend / share$0.15$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%28%
Portfolio after 10y$20.0K$30.3K
Annual income after 10y$0.20$4,689.40
Total dividends collected$206.00$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: FRSHY vs JNJ ($10,000, DRIP)

YearFRSHY PortfolioFRSHY Income/yrJNJ PortfolioJNJ Income/yrGap
1$10,803$102.65$10,592$272.30+$211.00FRSHY
2$11,611$51.82$11,289$357.73+$322.00FRSHY
3$12,449$26.03$12,123$472.89+$326.00FRSHY
4$13,334$13.04$13,141$629.86+$193.00FRSHY
5← crossover$14,274$6.53$14,408$846.81$134.00JNJ
6$15,276$3.26$16,021$1,151.60$745.00JNJ
7$16,347$1.63$18,122$1,588.22$1.8KJNJ
8$17,492$0.82$20,930$2,228.20$3.4KJNJ
9$18,717$0.41$24,792$3,191.91$6.1KJNJ
10$20,028$0.20$30,274$4,689.40$10.2KJNJ

FRSHY vs JNJ: Complete Analysis 2026

FRSHYStock

China Jinmao Holdings Group Limited, an investment holding company, operates in real estate and hotel businesses in Mainland China. It operates in four segments: City and Property Development, Commercial Leasing and Retail Operations, Hotel Operations, and Others. The City and Property Development segment develops city complexes and properties, as well as develops land. The Commercial Leasing and Retail Operations segment engages in the leasing of office and retail commercial premises. This segment has twelve investment properties with an area of approximately 0.80 million square meters. The Hotel Operations segment provides hotel accommodation, and food and beverages services. This segment operates ten luxury hotels that offers 3,968 guest rooms. The Others segment offers property management, and design and decoration services, as well as operates an observation deck. The company also engages in technology and services business. It holds 334 projects of city operations and property development, commercial leasing and retail operations, and hotel operations. The company was formerly known as Franshion Properties (China) Limited and changed its name to China Jinmao Holdings Group Limited in September 2015. China Jinmao Holdings Group Limited was incorporated in 2004 and is based in Wan Chai, Hong Kong.

Full FRSHY Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this FRSHY vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

FRSHY vs SCHDFRSHY vs JEPIFRSHY vs OFRSHY vs KOFRSHY vs MAINFRSHY vs ABBVFRSHY vs MRKFRSHY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.